Adamant Biomedical Investments’s Parexel International Corp PRXL Stock Holding History

Adamant Biomedical Investments’s Portfolio PRXL Stock Details PRXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	$2.22M	Buy	+40,000	New	+$2.31M	0.53%	62

Other funds holding PRXL

ACM

Americafirst Capital Management Roseville, California $74M AUM 13.49% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

GAM

Gotham Asset Management New York $32.7B AUM 27.65% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Adamant Biomedical Investments's PRXL Position: Q4 2014 in Review

Adamant Biomedical Investments opened a new position in Parexel International Corp (PRXL) in Q4 2014: 40,000 shares worth $2.22M. The stake represents 0.53% of the portfolio and ranks #62 among its holdings.

299 funds tracked by Wall St. Rank hold PRXL as of Q4 2014.

Adamant Biomedical Investments held 40,000 shares of Parexel International Corp worth $2.22M as of Q4 2014.
Parexel International Corp was a new Adamant Biomedical Investments position in Q4 2014.
Parexel International Corp made up 0.53% of Adamant Biomedical Investments's portfolio in Q4 2014, its #62 holding.
299 funds tracked by Wall St. Rank held Parexel International Corp as of Q4 2014.

Based on Adamant Biomedical Investments's 13F filing for Q4 2014, filed 13 Feb 2015.